Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure

January 3, 2026 updated by: Aya Ibrahim Elshenawy Elshenawy, Cairo University
this study aims to investigate the effect of low vs high volume- high intensity interval training on functional capacity and quality of life in chronic heart failure patients

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
    • Giza Governorate
      • Cairo, Giza Governorate, Egypt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Chronic stable heart failure patient with reduced ejection fraction (EF <40)
  2. Age Above 18 years old
  3. Both males and females
  4. The ability to provide informed consent

Exclusion Criteria:

  1. Based on the Scientific Statement from the American Heart Association: contraindications for exercise Testing and Training. (Fletcher et al., 2013)

    1. Acute myocardial infarction (MI), within 2 days
    2. Ongoing unstable angina
    3. Uncontrolled cardiac tachy or brady arrhythmia with hemodynamic compromise
    4. Active endocarditis
    5. Symptomatic severe aortic stenosis
    6. Decompensated heart failure
    7. Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis
    8. Acute myocarditis or pericarditis
    9. Acute aortic dissection
    10. Physical disability that precludes safe and adequate testing or training
    11. Known obstructive left main coronary artery stenosis
    12. Hypertrophic obstructive cardiomyopathy with severe resting gradient
    13. Recent stroke or transient ischemic attack
    14. Mental impairment with limited ability to cooperate
    15. Resting hypertension with systolic or diastolic blood pressures >200/110 mmHg
    16. Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and hyperthyroidism
  2. Acute decompensated heart failure NYHA class IV

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low volume high intensity interval training
This group will receive the usual care (standard medical treatment) in addition to LV-HIIT on a treadmill for 8 weeks, 2 sessions per week.
Other: low-volume high intensity interval training
Low-volume HIIT (LV-HIIT) is a particularly time-efficient subtype of interval training, which has gained increasing attention in recent years. As per the previous definition, these brief training protocols typically involve≤10 min of intense exercise within a session lasting≤30 min including warm-up, recovery phases between intervals, and cool-down
Drug: Standard medical treatment
standard medical treatment for chronic heart failure as per international guidlines
Experimental: high volume high intensity interval training
In this group, the patients will receive the usual care (standard treatment) in addition to HV-HIIT on a treadmill for 8 weeks, 2 sessions per week
Drug: Standard medical treatment
standard medical treatment for chronic heart failure as per international guidlines
Other: High volume high intensity interval training
long (2-4 min) bouts of high (not maximum) intensity exercise interspersed with recovery periods which have wide varieties in the protocols according to the intensity, duration, and number of intervals performed
Other: control group
It includes 15 patients who will receive standard medical treatment only
Drug: Standard medical treatment
standard medical treatment for chronic heart failure as per international guidlines

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
6 minute walk test
Time Frame: at enrolment and at the end of treatment at 8 weeks
self-paced submaximal field exercise test to assess submaximal functional capacity of the patient , the distance walked by the patient for six minutes will be measured by meters
at enrolment and at the end of treatment at 8 weeks
2D Echocardiographic parameters
Time Frame: at enrollment and at the end of treatment at 8 weeks

Left ventricle geometry: left ventricular end-diastolic diameter (LVEDD) mm, left ventricular end-systolic diameter (LVESD) mm, left ventricular end-systolic volume (LVESV) ml. and, left ventricular end-diastolic volume (LVEDV) ml.

Left ventricle Systolic function: left ventricular ejection fraction (LVEF) % Left ventricle Diastolic function :E wave cm/s: early diastolic mitral inflow velocity, A wave cm/s: diastolic mitral inflow velocity during late atrial contraction , E/A ratio
at enrollment and at the end of treatment at 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Minnesota living with heart failure questionnaire (MLHFQ)
Time Frame: at enrollment and at the end of treatment at 8 weeks
The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is the tool most widely used and recognized to assess HRQOL in adults with Hf, was developed in 1987 by Thomas Rector, focusing on the underlying relationship between pathophysiology, symptoms, functional limitations, and psychological distress, it measures the impacts of symptoms and treatment on different dimensions of HRQOL in HF patients.
at enrollment and at the end of treatment at 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 10, 2025

Primary Completion (Estimated)

June 6, 2026

Study Completion (Estimated)

June 6, 2026

Study Registration Dates

First Submitted

December 9, 2025

First Submitted That Met QC Criteria

January 3, 2026

First Posted (Actual)

January 8, 2026

Study Record Updates

Last Update Posted (Actual)

January 8, 2026

Last Update Submitted That Met QC Criteria

January 3, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • P.T.REC/012/005825

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Heart Failure

Clinical Trials on low-volume high intensity interval training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe